Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says

Insurers would be justified in imposing some initial limits on coverage of a new class of preventive migraine drugs, a new report from the Institute for Clinical and Economic Review said, citing insufficient evidence around the treatments' long-term safety and relative expense to current generic medicines.